



Long-term strategies for thyroid health monitoring after nuclear accidents

International Agency for Research on Cancer
Lyon, France

Kayo Togawa, MPH, PhD
togawak@iarc.fr

**On behalf of the IARC Expert Group on Thyroid
Health Monitoring after Nuclear Accidents**

International Agency for Research on Cancer



Background

- A nuclear power plant accident may result in a release of radionuclides including radioiodine.
- Exposure to radioiodine can cause various adverse health effects, including thyroid cancer.
- Important to consider how best to protect the thyroid health of the affected populations, as part of preparedness and response to any future nuclear accident
- IARC recognized the need for guidelines on how and whether to implement thyroid health monitoring after nuclear accidents involving release of radioiodine.

TM-NUC Project


Primary aim

- To develop recommendations on thyroid health monitoring after a nuclear accident

Approach

- Convened an international, multidisciplinary Expert Group (<http://tmnuc.iarc.fr>)
- The Expert Group reviewed the scientific evidence as well as the experience from past nuclear accidents in order to develop the recommendations.


International Agency for Research on Cancer



<http://publications.iarc.fr/571>

Cancer Screening

Cancer screening is the application of a screening test in an asymptomatic population to identify individuals with an abnormality suggestive of cancer, with the intent of reducing mortality and morbidity.



Thyroid Cancer in Adults

- Rare disease with a generally excellent prognosis
- Most common types: Papillary and follicular
- The expected 10-year disease-specific survival
98–100% for localized or regional disease, 85–95% for distant metastases (ages < 55 years)
- Screening identifies both benign thyroid nodules and thyroid cancers that will remain indolent, as well as those that will become clinically significant.
- Leads to an apparent rise in thyroid cancer incidence without proportionate mortality reduction

Screening an asymptomatic adult population for thyroid cancer is NOT recommended, because the harms outweigh the benefits.

Thyroid Cancer in Children and Adolescents

- Thyroid cancer is less common in children and adolescents than in adults.
- Papillary thyroid cancer-specific 30-year survival is approximately 99–100% irrespective of sex or presence of regional lymph node metastasis at presentation, with a minimal decrease in survival (to 97%) for patients with distant metastasis.
- For children and adolescents exposed to Chernobyl fallout, thyroid cancer-specific survival was 98–99%.

Screening populations of children and adolescents regardless of risk levels is expected to also result in issues related to overdiagnosis without clear public health benefits.

Expert Group Recommendation No. 1

The Expert Group recommends *against* population thyroid screening* after a nuclear accident.

The Expert Group defines “population thyroid screening” as actively recruiting all residents of a defined area to participate in thyroid examinations and subsequent diagnostic or follow-up tests as indicated.

Potential Benefits and Harms in High-Risk Groups

- Elevated risk in those exposed to radiation during childhood or adolescence
- Limited evidence on benefits of early detection in high-risk children and adolescents
- After the Chernobyl accident – favourable prognosis
- May have required less extensive treatment if the thyroid cancer had been detected earlier
- Not possible to predict with certainty which cancers will progress to an advanced state
- Risk of undergoing treatment without potential clinical benefit for cancers that may have remained indolent

Expert Group Recommendation No. 2

The Expert Group recommends that consideration be given to offering a long-term thyroid monitoring programme for higher-risk individuals* after a nuclear accident.

* The Expert Group defines “higher-risk individuals” as individuals exposed in utero or during childhood or adolescence (younger than 19 years) with a thyroid dose of 100–500 mGy or more.

Thyroid Monitoring Programme

- Thyroid monitoring programme includes:
 - education to improve health literacy
 - registration of participants
 - centralized data collection from thyroid examinations and clinical management
- Should be extended through adulthood
- An elective activity – the decision about whether to participate or to stop is individual preference-sensitive.
- Has to include a shared decision-making process to enable decision-making that is consistent with the person's values, preferences, and context

Remarks

- The practical definition of a thyroid dose of 100–500 mGy as an actionable level for offering inclusion in the long-term thyroid monitoring programme should not be confused with radiation protection limits.
- This does not mean that nothing should be offered to an individual with a thyroid dose below the actionable level.
- Further research is needed, and the optimal actionable level may need to be revised as new evidence emerges.

Considerations

1. Monitoring infrastructure to assess the likely health consequences of release of radioactive substances
2. Dosimetric monitoring
3. Oral administration of potassium iodide (thyroid blocking)
4. Education/risk communication to the population living in the vicinity of a nuclear power plant

Other considerations may also be important, such as socioeconomic implications, health-care resources, and social values. The final decision should be made jointly by the government, the relevant authorities, and the society affected by the nuclear accident.

Acknowledgements

Expert Group

Hyeong Sik Ahn
Anssi Auvinen
Andrew J. Bauer
Juan P. Brito
Louise Davies
Ausrele Kesminiene
Dominique Laurier
Evgenia Ostroumova
Furio Pacini
Christoph Reiners
Sergey Shinkarev
Geraldine Thomas
Mykola Tronko
Salvatore Vaccarella

Specialists

Zhanat Carr
André Ilbawi
Hiroki Shimura

Advisers

Enora Clero
Silvia Franceschi
Maria Perez
Catherine Sauvaget

Project secretary

Catherine Chassin

Production team

Jennifer Brandt
Sylvia Lesage
Karen Müller


Financial support

The Japanese Ministry of the Environment

Management of funds

Nuclear Safety Research Association of Japan

International Agency for Research on Cancer



<http://publications.iarc.fr/571>

Selected references

- Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, et al.; US Preventive Services Task Force (2017). Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 317(18):1882–7.
- Brito JP, Al Nofal A, Montori VM, Hay ID, Morris JC (2015). The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in Olmsted County, Minnesota during 1935 through 2012. *Thyroid*. 25(9):999–1007.
- Clement SC, Kremer LCM, Verburg FA, Simmons JH, Goldfarb M, Peeters RP, et al. (2018). Balancing the benefits and harms of thyroid cancer surveillance in survivors of childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. *Cancer Treat Rev*. 63:28–39.
- Davies L, Ouellette M, Hunter M, Welch HG (2010). The increasing incidence of small thyroid cancers: where are the cases coming from? *Laryngoscope*. 120(12):2446–51.
- Golpanian S, Perez EA, Tashiro J, Lew JI, Sola JE, Hogan AR (2016). Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients. *Pediatr Surg Int*. 32(3):201–8.
- Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB (2010). Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. *World J Surg*. 34(6):1192–202.
- IARC Expert Group on Thyroid Health Monitoring after Nuclear Accidents (2018). Thyroid health monitoring after nuclear accidents. IARC Technical Publication No. 46. Lyon: International Agency for Research on Cancer.

Selected references

- Perrier ND, Brierley JD, Tuttle RM (2018). Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 68(1):55–63.
- Reiners C, Biko J, Haenscheid H, Hebestreit H, Kirinjuk S, Baranowski O, et al. (2013). Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 98(7):3039–48.
- Shimura H, Sobue T, Takahashi H, Yasumura S, Ohira T, Ohtsuru A, et al.; Thyroid Examination Unit of the Radiation Medical Center for the Fukushima Health Management Survey Group (2018). Findings of thyroid ultrasound examination within 3 years after the Fukushima Nuclear Power Plant accident: the Fukushima Health Management Survey. *J Clin Endocrinol Metab.* 103(3):861–9.
- Tuttle RM, Vaisman F, Tronko MD (2011). Clinical presentation and clinical outcomes in Chernobyl-related paediatric thyroid cancers: What do we know now? What can we expect in the future? *Clin Oncol (R Coll Radiol).* 23(4):268–75.
- WHO (2002). National cancer control programmes: policies and managerial guidelines. 2nd ed. Geneva, Switzerland: World Health Organization.
- WHO (2007). Cancer control: early detection. WHO guide for effective programmes. Geneva, Switzerland: World Health Organization.
- Yamashita S, Suzuki S, Suzuki S, Shimura H, Saenko V (2018). Lessons from Fukushima: latest findings of thyroid cancer after the Fukushima Nuclear Power Plant accident. *Thyroid.* 28(1):11–22.